CHNC’s Shareholders Rewarded with Astonishing Investment

HOUSTON, TX, Sept. 22, 2021 (GLOBE NEWSWIRE) — via NewMediaWire – China Infrastructure Construction Corp. https://www.chnc-hdh.com/  (dba Cannabis Bioscience International Holdings), announced today that its share price increase over the past year has led to a return on investment (ROI) of 2,550%. In simple terms, a $1,000 investment in CHNC on September 17, 2020 when the price per share was $0.0002, by the same time this year, last Friday, September 17, 2021 was worth $26,500 as the share price closed at $0.0053, producing a profit of $25,500. 

Although this has been an extraordinary achievement, “CHNC still faces several challenges to reach the accomplishment and stability needed in 2022,” says Henry Levinski, CHNC´s Treasurer. With the clock ticking and with the understanding that there are only three months left to end this year, CHNC continues with all hands-on deck to enhance and solidify the productivity, research, technology, and medical alliances still needed for the company before the end of 2021.  

Overall, this includes the execution of the action plan for our Cannabis World Journals magazine, the growth of our relationship with Sympla, Walmart, and the Amazons of the world for our globally distributed content (including audiobooks, e-books and educational videos), the management of our sleep center, and our clinical studies. We cannot fail and we cannot risk being distracted by new products, except those in our 2022 pipeline which align with our medical and educational purposes. Our goals remain crystal clear. 

“Each one of our revenue-generating centers has to perform in the manner that they were designed to perform,” says Anne Graham, attorney at law and CHNC’s Vice- President of International Markets. Even though we feel proud of our growth so far, we realize that we cannot spend time in our comfort zone. It has been this exact mentality which led us to provide for our investors the astounding progress experienced, which we intend to continue to improve through our operational systems during 2022.

According to Nerdwallet.com, the average stock market return has been about 10% per year for nearly the last century. The S&P 500 is often considered the benchmark measure for annual stock market returns. According to BusinessInsider.com, the medium return of the S&P 500 for 2020 was just over 18%. Given the figures above, “we are gratified to see the gathering of investor support for our evolving company,” adds Dr. Deepika, Director of CHNC Research Clinical Center.

During pandemic and turbulent times CHNC has learned to become a self-healing and self-correcting system and now the company is virtually utterly ready for 2022 with the mantra of the corporation being “Execute, execute, execute” in order to develop a healthy bottom line.

We have broken a tremendous amount of ground, but with the road we have paved, our stock performance has charted its course, and it has definitely not disappointed, particularly if we notice the increase in the closing price from September 17, 2020, to September 17, 2021, and we equivalence to the investment return of some of the most successful and stable companies in the financial field. To further illustrate our point, let us review some of the stock market indexes that serve as a staple for the financial market. A fact is a stubborn thing that cannot be argued with.

  • S&P 500; Closing Price 09/17/2020: $3,357.01 – Closing Price 09/17/2021: $4,432.99  //  32.05%
  • Dow Jones; Closing Price 09/17/2020: $27,901.98 – Closing Price 09/17/2021: $34,584.88 //  23.95%
  • NASDAQ-100; Closing Price 09/17/2020: $11,080.95 – Closing Price 09/17/2021: $15,333.47  //  38.38%
  • NYSE; Closing Price 09/17/2020: $12,948.45 – Closing Price 09/17/2021: $16,460.35  //  27.12%
  • OTC Markets Group; Closing Price 09/17/2020: $30.04 – Closing Price 09/17/2021: $46.25  //   53.96%
  • CHNC;  CLOSING PRICE 09/17/2020:  $0.0002  – CLOSING PRICE 09/17/2021:  $0.0053   //   2550% ROI

“We are no longer a candle in the wind but realize that the markets are agnostic and only identify with healthy financials and innovation. Our trend of caution will continue to be especially pronounced but our ethics and emotional intelligence will keep our company on steroids and will allow us to prevail and be successful,” says Dante Picazo, CEO.  

Safe Harbor Statement

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “projects,” “intends,” and similar phrases. Forward-looking statements involve risks and uncertainties that could cause actual results to differ from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of geopolitical conditions, competition, changes in technology and methods of marketing, and various other factors beyond the company’s control.

For more information contact us at:
info@pharmacologyuniversity.com
817/528-2475 for English
214/733-0868 for Spanish

Related Posts